Parkinsonism & Related Disorders
Volume 15, Issue 1 , Pages 41-46 , January 2009

Smoking and tea consumption delay onset of Parkinson's disease

  • Boris Kandinov

      Affiliations

    • Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Nir Giladi

      Affiliations

    • Department of Neurology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Neurology, Sourasky Medical Center, Tel Aviv, Israel
    • ,
  • Amos D. Korczyn

      Affiliations

    • Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel
    • Department of Neurology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Department of Neurology, Sourasky Medical Center, Tel Aviv, Israel
    • Corresponding Author InformationCorresponding author. Department of Physiology and Pharmacology, Sieratzki Chair of Neurology, Tel Aviv University, Ramat Aviv 69978, Israel. Tel.: +972 3 6974229; fax: +972 3 6409113.

Received 19 July 2007 ,Revised 5 January 2008 ,Accepted 18 February 2008.

References 

  1. Dorn HF. The mortality of smokers and nonsmokers. In: Proceedings of the social statistics section. vol 1:American Statistical Association; 1958;p. 34–71
  2. Dorn HF. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep. 1959;74:581–593
  3. Kahn HA. The Dorn study of smoking and mortality among US veterans: report on eight and one-half years of observation. In:  Haenszel W editors. Epidemiologic approaches to the study of cancer and other chronic diseases. National Cancer Institute Monograph. vol 19:Bethesda, MD: US Department of Health, Education and Welfare; 1966;p. 1–25
  4. Hammond EC. Smoking in relation to the death rates of one million men and women. In:  Haenszel W editors. Epidemiologic approaches to the study of cancer and other chronic diseases. National Cancer Institute Monograph. vol 19:Bethesda, MD: US Department of Health, Education and Welfare; 1966;p. 127–204
  5. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson's disease. Am J Epidemiol. 1968;88:149–158
  6. Kessler , Diamond EL. Epidemiologic studies of Parkinson's disease. I. Smoking and Parkinson's disease: a survey and explanatory hypothesis. Am J Epidemiol. 1971;94:16–25
  7. Kessler . Epidemiologic studies of Parkinson's disease. III. A community-based survey. Am J Epidemiol. 1972;96:242–254
  8. Ansari KA, Johnson A. Olfactory function in patients with Parkinson's disease. J Chronic Dis. 1975;28:493–497
  9. Doll R, Peto R. Mortality in relation to smoking: 20 years observations on male British doctors. BMJ. 1976;2:1525–1536
  10. Baumann RJ, Jameson HD, Mckean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson's disease: a comparison of cases with matched neighbors. Neurology. 1980;30:839–843
  11. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry. 1982;45:577–581
  12. Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983;33:815–824
  13. Marttila RJ, Rinne UK. Smoking and Parkinson's disease. Acta Neurol Scand. 1980;62:322–325
  14. Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson's disease. Am J Epidemiol. 1981;114:191–200
  15. Golbe LI, Cody RA, Duvoisin RC. Smoking and Parkinson's disease. Search for a dose–response relationship. Arch Neurol. 1986;43:774–778
  16. Rajput AH, Offord KP, Beard CM, Kurland LT. A case–control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease. Neurology. 1987;37:226–232
  17. Aquilonius S-M. Parkinson's disease – etiology and smoking. Prog Brain Res. 1989;79:329–333
  18. Riggs JE. Cigarette smoking and Parkinson's disease: the illusion of a neuroprotective effect. Clin Neuropharmacol. 1992;15:88–99
  19. Tanner CM, Chen B, Wang WZ, Peng ML, Liu ZL, Liang XL, et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci. 1987;14:419–423
  20. Sasco AJ, Paffenbarger RS. Smoking and Parkinson's disease. Epidemiology. 1990;1:460–465
  21. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology. 1993;43:1173–1180
  22. Tzourio C, Rocca WA, Breteler MM, Baldereschi M, Dartigues JF, Lopez-Pousa S, et al. Smoking and Parkinson's disease. An age-dependent risk effect?. Neurology. 1997;49:1267–1272
  23. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. Mov Disord. 1999;14:928–939
  24. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology. 1993;43:1150–1158
  25. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol. 1994;139:1129–1138
  26. De Michele G, Filla A, Volpe G, De Marco V, Gogliettino A, Ambrosio G, et al. Environmental and genetic risk factors in Parkinson's disease: a case–control study in southern Italy. Mov Disord. 1996;11:17–23
  27. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case–control study in Taiwan. Neurology. 1997;48:1583–1588
  28. Hellenbrand W, Seidler A, Robra B-P, Vieregge P, Oertel WH, Joerg J, et al. Smoking and Parkinson's disease: a case–control study in Germany. Int J Epidemiol. 1997;26:328–339
  29. Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. A case–control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. Neurotoxicology. 1998;19:709–712
  30. Gorell JM, Rybicki A, Johnson CC, Peterson CL. Smoking and Parkinson's disease: a dose–response relationship. Neurology. 1999;52:115–119
  31. Behari M, Srivastava AK, Das RR, Pandey RM. Risk factors of Parkinson's disease in Indian patients. J Neurol Sci. 2001;190:49–55
  32. Tan EK, Tan C, Fook-Chong SMC, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci. 2003;216:163–167
  33. Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk factors for Parkinson's disease: case–control study in the province of Caceres, Spain. Acta Neurol Scand. 1994;89:164–170
  34. Hellenbrand W, Seidler A, Boeing H, Robra BP, Vieregge P, Nischan P, et al. Diet and Parkinson's disease I: a possible role for the past intake of specific foods and food groups. Results from a self-administered food frequency questionnaire in a case–control study. Neurology. 1996;47:636–643
  35. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case–control study in southeastern Sweden. Mov Disord. 1999;14:28–37
  36. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case–control study. Neurology. 2000;55:1350–1358
  37. Preux PM, Condet A, Anglade C, Druet-Cabanac M, Debrock C, Macharia W, et al. Parkinson's disease and environmental factors. Matched case–control study in the Limousin region, France. Neuroepidemiology. 2000;19:333–337
  38. Jimenez-Jimenez FJ, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case–control study. Mov Disord. 1992;7:339–344
  39. Checkoway H, Powers K, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol. 2002;155:732–738
  40. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson's disease. JAMA. 2000;283:2674–2679
  41. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 2001;50:56–63
  42. Chan DKY, Woo J, Ho SC, Pang CP, Law LK, Ng PW, et al. Genetic and environmental risk factors for Parkinson's disease in a Chinese population. J Neurol Neurosurg Psychiatry. 1998;65:781–784
  43. Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. Parkinsonism Relat Disord. 2007;13:243–245
  44. Hughes AJ, Daniel SE, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184
  45. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442
  46. Armitage P, Berry G. Statistical methods in medical research. 2nd ed.. Oxford: Blackwell Scientific Publications; 1987;
  47. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community?. J Neurol Neurosurg Psychiatry. 2002;73:529–534
  48. Hill AB. The environment and disease: association or causation?. Proc R Soc Med. 1965;58:295–300
  49. Hancock BD, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007;64:576–580
  50. Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, et al. A case–control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology. 1986;36:284–288
  51. Diana JN. Tobacco smoking and nutrition. Ann N Y Acad Sci. 1993;686:1–11
  52. Seppa T, Ahtee L. Comparison of the effects of epibatidine and nicotine on the output of dopamine in the dorsal and ventral striatum of freely-moving rats. Arch Pharmacol. 2000;362:444–447
  53. Minana MD, Montoliu C, Llansola M, Grisolía S, Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology. 1998;37:847–857
  54. Quik M, Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol. 2000;393:223–230
  55. Linert W, Bridge MH, Huber M, Bjugstad KB, Grossman S, Arendash GW. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's disease. Biochem Biophys Acta. 1999;1454:143–152
  56. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor RR, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379:733–736
  57. Caldwell CR. Oxygen radical absorbance capacity of the phenolic compounds in plant extracts fractionated by high-performance liquid chromatography. Anal Biochem. 2001;293:232–238
  58. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 1999;22:123–144
  59. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001;78:1073–1082
  60. Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against abeta toxicity and PKC dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (−)-epigallocatechin-3-gallate. FASEB J. 2003;17:952–954
  61. Svenningsson P, Le Moine C, Fapisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog Neurobiol. 1999;59:355–396
  62. Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS–NO pathway. Biol Psychiatry. 2007;62:1353–1362

PII: S1353-8020(08)00093-X

doi: 10.1016/j.parkreldis.2008.02.011

Parkinsonism & Related Disorders
Volume 15, Issue 1 , Pages 41-46 , January 2009

Article Tools

* Image Usage & Resolution